What National Academies Found on Compounded Hormones
Compounded, bioidentical, custom: the words on a hormone menu sound close, and close wording is easy to misread. This note reads one source slowly so a Land Park reader can tell a cited finding from a sales line.
Two descriptions, side by side
Put the two common phrasings next to each other and the gap shows up fast.
- Compounded bioidentical hormone therapy. This is the wording the National Academies committee used in its own name.
- Custom or personalized hormones. This is menu language. It tells you a blend was tailored, but not what a review found about that blend.
The first phrase points to a body of work you can look up. The second describes an experience. Before treating them as the same thing, check which one a source actually uses. For general background on the subject, MedlinePlus has a page called Hormone Therapy for Menopause that sits outside any clinic's sales copy.
What the committee's text states
The National Academies states the origin of the work plainly. Its committee "was formed at the request of FDA to assess the clinical utility of cBHT."
Read it line by line. The request came from the U.S. Food and Drug Administration, and the thing it asked the committee to assess was clinical utility. It does not say what the committee concluded, so it cannot be quoted as a verdict either way.
The National Academies adds a second line that matters more to a patient: "However, the committee also grappled with the concern that for the large patient population using cBHT, it is currently impossible for their clinicians to provide evidence-based guidance on the effectiveness or safety of each unique formulation."
The words to slow down on are "each unique formulation." The concern is about guidance for individual formulations. The sentence does not say any formulation works, and it does not say any is unsafe.
Where a description outruns the source
Sort every claim you meet into two piles. In the first pile are claims that trace to a cited review, named by publisher, like the two sentences above. In the second pile is everything else a flyer says about a custom blend.
Until a source is named, the second pile is marketing language. A line promising a blend tailored to you belongs in that pile unless someone shows you the review behind it. The committee's own wording about each unique formulation is a good reason to ask for that review.
For how the regulator frames compounding in general, read the FDA's questions and answers on compounding and compare its phrasing with the menu in front of you.
The question to ask the clinic
Ask the clinic one thing: which published review supports the effectiveness and safety of this exact formulation? A useful answer names a publisher and a document you can open yourself.
If the answer is a brand story or a general reassurance, treat the claim as unverified and keep comparing.